## PATENT APPLICATION ATTORNEY DOCKET 29715/35152R

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Reissue Application of: Giroir et al	. ) I hereby certify that this paper and the
	) documents identified herein are being
U.S. Patent No. 5,990,086	) deposited with the United States Postal
	) Service on November 23, 2001, in an
Issued Date: November 23, 1999	) envelope addressed to the Assistant
	) Commissioner of Patents, Washington,
For: Therapeutic Uses of BPI Protein	) D.C. 20231 utilizing the "Express Mail
Products for Human Meningococcemia	) Post Office to Addressee" service of the
	) United States Postal Service under
Filed: Herewith	Mailing Label No. <u>ELS644651784</u> 3
Probable Group Art Unit: 1646	& down fer
•	Thomas & Kim
Probable Examiner: A. Mohamed	~ / / (wincus s. ////

## CONSENT OF ASSIGNEE TO REISSUE APPLICATION

Box REISSUE Commissioner for Patents Washington, D.C. 20231

Sir:

The undersigned, on behalf of XOMA Technology Ltd., the assignee of an undivided interest in the above-identified U.S. patent, the invention described therein and improvements thereof, any and all applications on such inventions or improvements, and any and all patents obtained from such applications, hereby assents to the accompanying application for reissue.

Respectfully submitted,

Ву	: Chitale Mayl
	Christopher J. Margolfn
	Vice President, General Counsel and Secretary
	XOMA Technology Ltd.
. 2001	

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Reissue Application of: Giroir et al. I hereby certify that this paper and the documents identified herein are being U.S. Patent No. 5,990,086 deposited with the United States Postal Service on November 23, 2001, in an envelope addressed to the Assistant Issued Date: November 23, 1999 Commissioner of Patents, Washington, For: Therapeutic Uses of BPI Protein D.C. 20231 utilizing the "Express Mail Products for Human Meningococcemia Post Office to Addressee" service of the United States Postal Service under Mailing Mabel No. EL564465178US Filed: Herewith Probable Group Art Unit: 1646

CERTIFICATE UNDER 37 C.F.R. §3.73(b)

Box REISSUE Commissioner for Patents Washington, D.C. 20231

Probable Examiner: A. Mohamed

Sir:

XOMA Technology Ltd., a Bermuda company, having a registered office at Clarendon House, 2 Church Street, Hamilton HM11, Bermuda, certifies that it is the assignee of an undivided interest in and to U.S. Application Serial No. 09/203,159, filed December 1, 1998, which issued on November 23, 1999 as U.S. Patent No. 5,990,086, in the names of inventors Brett P. Giroir and Patrick J. Scannon, for Therapeutic Uses of BPI Protein Products for Human Meningococcemia.

The chain of title from the inventor Patrick J. Scannon to XOMA Technology Ltd. is evidenced by the following. First, inventor Scannon assigned his entire right, title and interest in, among others, the above-identified application and the underlying invention to XOMA Corporation by an assignment, which was recorded on February 12, 1999, at Reel 9767, Frame 0521. Second, XOMA Corporation has become XOMA Ltd., a Bermuda company, through a merger and change in domicile and name. Exhibit A shows the documentation of this merger and change in domicile. Third, XOMA Ltd. assigned all of its

right, title and interest in, among others, the above-identified application and the underlying invention to XOMA Technology Ltd. through an assignment executed on December 6, 1999, a copy of which is attached hereto as Exhibit B. In light of this evidence of ownership of an undivided interest by XOMA Technology Ltd., it is submitted that XOMA Technology Ltd. is an assignee required to consent to the filing of the reissue application submitted herewith and does hereby consent as set forth in the accompanying Consent of Assignee to Reissue.

The undersigned, Christopher J. Margolin, is authorized to act on behalf of XOMA Technology Ltd.

By: Christopher J. Margolin
Vice President, General Counsel and Secretary
XOMA Technology Ltd.